アジア太平洋地域の二次性高シュウ酸尿症薬市場、タイプ別（レロキサリアゼ、チアジド系利尿薬、サプリメント）、薬の種類別（処方薬と市販薬）、人口タイプ別（小児と成人）、エンドユーザー別（病院、専門クリニック、在宅医療など）、流通チャネル別（病院薬局、小売薬局、オンライン薬局など）、国別（日本、中国、オーストラリア、インド、韓国、シンガポール、インドネシア、タイ、マレーシア、フィリピン、ベトナム、その他のアジア太平洋地域）業界動向と2028年までの予測
市場分析と洞察:アジア太平洋地域の二次性高シュウ酸尿症治療薬市場
二次性高シュウ酸尿症治療薬市場は、2021年から2028年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に67.3%のCAGRで成長し、2020年の2億1,690万米ドルから2028年には83億4,646万米ドルに達すると分析しています。二次性高シュウ酸尿症の標的治療は需要が高く、医薬品開発に注力する企業への研究開発投資が世界の二次性高シュウ酸尿症治療薬市場の主要な推進力となる可能性が高いです。
腸の問題により高濃度のシュウ酸が吸収されることで様々な臓器や組織に影響を及ぼす多因子疾患は、二次性高シュウ酸尿症、または重症化すると腸性高シュウ酸尿症と呼ばれます。この疾患は食事や何らかの疾患による吸収不良と深く関係しており、シュウ酸またはシュウ酸の前駆体であるビタミン Cの摂取が主な原因の 1 つです。二次性高シュウ酸尿症の重要な要因であることが知られている細菌である Oxalobacter formigenes は、機能要件を満たすためにシュウ酸を主要なエネルギー要素として使用し、この疾患の発生に重要な役割を果たしています。現在の世界的な薬物療法の状況では、抗生物質は最も多く処方される薬の 1 つです。抗生物質を使用すると、腸内細菌叢を妨げてこの細菌の定着を阻害し、吸収不良のリスクを高めるため、腸の微小環境に影響が見られます。これが二次性高シュウ酸尿症につながる可能性があります。
Vitamin B6, calcium, magnesium and citrate supplement along with probiotics are prescribed in secondary hyperoxaluria with preventive care and availability of low oxalate food available in the market. The targeted treatment for secondary hyperoxaluria is in high demand, R&D investment in companies focusing on drug development, low dietary awareness in society and loss of oxalobacter formigenes due to increased usage of antibiotics are expected to drive the secondary hyperoxaluria drug market growth. Moreover, difficulty for maintaining low oxalate food and increasing number of bariatric surgery in the bolsters the secondary hyperoxaluria drug market growth.
The secondary hyperoxaluria drug market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Secondary Hyperoxaluria Drug Market Scope and Market Size
The secondary hyperoxaluria drug market is categorized into five notable segments which are based on the type, drug type, population type, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of type, the secondary hyperoxaluria drug is segmented into reloxaliase, thiazide diuretics and supplements. In 2021, supplements segment is dominating the secondary hyperoxaluria drug market as there is no targeted therapy available. However, some products are in the clinical trials and are expected to come to interstate commerce in near future. So management of the disease is done through supplements and dietary restrictions. Calcium supplements, magnesium supplements and other supplements serve as primary line of treatment along with dietary restrictions, fluid intake and probiotics which are used to maintain the gut flora.
- On the basis of drug type, the secondary hyperoxaluria drug is segmented into prescription and over the counter. In 2021, over the counter segment is dominating in the global secondary hyperoxaluria drug market as among all the products available for the treatment are generally supplements. After the successful diagnosis of the disease, the treatments suggested by physicians are available over the counter and a prescription is not necessary for these supplements to be consumed with regular diet owing to the reason for over the counter to dominate in the secondary hyperoxaluria drug market.
- On the basis of population type, the secondary hyperoxaluria drug is segmented into children and adults. In 2021, adults segment is dominating in the global secondary hyperoxaluria drug market as the diagnosis for secondary hyperoxaluria adults is usually carried out for indications of kidney stone and high oxalate excretion in the urine along with UTI. The prevalence of kidney stones is uncommon in children and the number of cases for the disease is comparatively very low when compared with adults.
- On the basis of end user, the secondary hyperoxaluria drug is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, home healthcare segment is dominating the global secondary hyperoxaluria drug market owing to the fact that the current treatment comprises of supplements and thiazide diuretics. These treatment products are taken by patients at home without the help of any medical professional and supervision hence dominating the segment of the secondary hyperoxaluria drug market.
- On the basis of distribution channel, the secondary hyperoxaluria drug is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, retail pharmacies segment is dominating in the secondary hyperoxaluria drug market as the numbers of these pharmacies are very high and increasing with year passing. They cater to majority of patients for buying drugs in traditional consumer purchase style. Moreover, retail pharmacies are focusing on broadening their services for better customer service.
Secondary Hyperoxaluria Drug Market Country Level Analysis
The secondary hyperoxaluria drug market is analysed and market size information is provided by country, type, drug type, population type, end user and distribution channel.
The countries covered in the secondary hyperoxaluria drug market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam and Rest of Asia-Pacific.
Asia-Pacific is expected to grow with the CAGR in the forecasted periods as in the Asia-Pacific’s countries demand for secondary hyperoxaluria drug product is increasing very rapidly with the urbanization and availability of products. Japan is expected to dominate in the market in the Asia-Pacific market. Japan is one of the leading countries to inculcate secondary hyperoxaluria drug market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Number of Bariatric Surgery and Rising Disposable Income are Creating New Opportunities for Players in the Secondary Hyperoxaluria Drug Market
Secondary hyperoxaluria drug market also provides you with detailed market analysis for every country growth in particular industry with secondary hyperoxaluria product sales, impact of advancement in the secondary hyperoxaluria drug and changes in regulatory scenarios with their support for the secondary hyperoxaluria drug market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Secondary Hyperoxaluria Drug Market Share Analysis
Secondary hyperoxaluria drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to secondary hyperoxaluria drug market.
The major companies providing secondary hyperoxaluria drug market are Nestlé, GlaxoSmithKline plc, Bayer AG, Pharmavite, Solgar Inc., Mission Pharmacal Company, Oystershell, Allena Pharmaceuticals, Inc., Celebrate Vitamins, Entring, LLC, OxThera, Renew Life Formulas, Inc., Synlogic, TIENS, Amway Corp., Infinitus (China), Now Foods, Nature's Bounty, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players with capital investment for secondary hyperoxaluria is bridging the gap between secondary hyperoxaluria and its drugs.
- In November 2020, Bayer AG announced to start a G4A Digital health partnership program with the four new start-ups with a focus on cardio metabolic and renal disease, oncology and women’s health. This partnership is to shape the future of healthcare and to support the start-ups and will increase the strategic business development for the company.
- 2020年8月、PharmaviteのブランドであるNurish by Natureは、Walgreensを通じてパーソナライズされたビタミンとサプリメントを開発するために、Walgreensとの初めてのコラボレーションを発表しました。この開発は、同社が個人の栄養不足を補うのに役立ち、同社の将来の成長を促進するのに役立ちます。
市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、二次性高シュウ酸尿症薬の企業市場が強化され、組織にとっても二次性高シュウ酸尿症薬市場への提供を改善するメリットがもたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
5 REGULATORY SCENARIO OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
5.1 REGULATORY FRAMEWORK FOR PROBIOTICS
5.2 REGULATORY FRAMEWORK FOR EUROPE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TARGETED TREATMENT FOR SECONDARY HYPEROXALURIA IS IN HIGH DEMAND
6.1.2 R&D INVESTMENT IN COMPANIES FOCUSING ON DRUG DEVELOPEMENT
6.1.3 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY
6.1.4 INCREASED NUMBER OF CASES FOR SECONDARY HYPEROXALURIA
6.1.5 LOSS OF OXALOBACTER FORMIGENES
6.2 RESTRAINTS
6.2.1 LIMITED OPERATING REVENUE
6.2.2 HIGH COST OF TREATING SECONDARY HYPEROXALURIA
6.2.3 LIMITED SECONDARY THERAPEUTICS OPTION FOR TREATMENT
6.3 OPPORTUNITIES
6.3.1 DIFFICULTY IN MAINTAINING LOW OXALATE DIET
6.3.2 INCREASING NUMBER OF BARIATRIC SURGERY
6.3.3 REGULATORY SUPPORT FOR APPROVAL
6.3.4 RISING DISPOSABLE INCOME
6.4 CHALLENGES
6.4.1 DELAY IN DIAGNOSIS OF DISEASE LEADING TO NEED FOR RENAL REPLACEMENT
6.4.2 INCREASE FITNESS AWARENESS AMONG PEOPLE
6.4.3 INCREASE FLUID INTAKE AS A PREVENTIVE MEASURES
7 COVID-19 IMPACT ON ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
7.1 OVERVIEW
7.2 PRICE IMPACT
7.3 IMPACT ON DEMAND
7.4 IMPACT ON SUPPLY CHAIN
7.5 STRATEGIC DECISIONS FOR MANUFACTURERS
7.6 CONCLUSION
8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE
8.1 OVERVIEW
8.2 SUPPLEMENTS
8.2.1 OXALATE BINDING AGENTS
8.2.1.1 CALCIUM SUPPLEMENTS
8.2.1.2 MAGNESIUM SUPPLEMENTS
8.2.1.3 OTHERS
8.2.2 CITRATE SUPPLEMENTS
8.2.3 PYRIDOXINE SUPPLEMENTS
8.2.4 PROBIOTICS
8.3 THIAZIDE DIURETICS
8.4 RELOXALIASE
9 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 OVER THE COUNTER
9.3 PRESCRIPTION
10 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE
10.1 OVERVIEW
10.2 ADULTS
10.3 CHILDREN
11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER
11.1 OVERVIEW
11.2 HOME HEALTHCARE
11.3 HOSPITALS
11.4 SPECIALTY CLINICS
11.5 OTHERS
12 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 RETAIL PHARMACIES
12.3 HOSPITAL PHARMACIES
12.4 ONLINE PHARMACIES
12.5 OTHERS
13 ASIA-PACIFIC SECONDARY HYPEROXLURIA DRUG MARKET, BY GEOGRAPHY
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 INDIA
13.1.4 AUSTRALIA
13.1.5 SOUTH KOREA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 VIETNAM
13.1.12 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15 COMPANY PROFILE
15.1 NESTLE
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 GLAXOSMITHKLINE PLC
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BAYER AG
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 NOW FOODS
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.5 SOLGAR INC.
15.5.1 COMPANY SNAPSHOT
15.5.2 COMPANY SHARE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 PHARMAVITE
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 INFINITUS (CHINA)
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 MISSION PHARMACAL COMPANY
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 .RECENT DEVELOPMENT
15.9 OYSTER SHELL
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 ALLENA PHARMACEUTICALS, INC.
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENTS
15.11 AMWAY CORP.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 CELEBRATE VITAMINS
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 ENTRING, LLC
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENTS
15.14 NATURE’S BOUNTY
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 OXTHERA
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENT
15.16 RENEW LIFE FORMULAS, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENTS
15.17 SYNLOGIC
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENTS
15.18 TIENS
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
LIST OF TABLES
TABLE 1 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 5 ASIA-PACIFIC OXALATE BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2019-2028 (USD MILLION)
TABLE 6 ASIA-PACIFIC THIAZIDE DIURETICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC RELOXALIASE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC OVER THE COUNTER IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC PRESCRIPTION IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC ADULTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC CHILDREN IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC HOME HEALTHCARE IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC HOSPITALS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC SPECIALTY CLINICS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC OTHERS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC RETAIL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC HOSPITAL PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC ONLINE PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC OTHERS PHARMACIES IN SECONDARY HYPEROXALURIA DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 28 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 29 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 32 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 33 CHINA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 34 CHINA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 35 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 36 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 37 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 CHINA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 JAPAN SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 41 JAPAN OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 42 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 43 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 44 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 JAPAN SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 INDIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 INDIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 50 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 51 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 52 INDIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 53 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 AUSTRALIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 AUSTRALIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 57 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 58 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 59 AUSTRALIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 60 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 61 SOUTH KOREA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 SOUTH KOREA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 64 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 65 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 SOUTH KOREA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 SINGAPORE SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 SINGAPORE OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 71 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 72 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 SINGAPORE SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 THAILAND SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 THAILAND OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 78 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 79 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 80 THAILAND SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 81 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 82 MALAYSIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 83 MALAYSIA OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 84 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 85 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 86 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 87 MALAYSIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 88 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 INDONESIA SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SWITZRLAND OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 92 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 93 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 94 INDONESIA SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 95 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 PHILIPPINES SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 PHILIPPINES OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 99 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 100 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 PHILIPPINES SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 102 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 103 VIETNAM SUPPLEMENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 VIETNAM OXALATE-BINDING AGENTS IN SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 105 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY DRUG TYPE, 2019-2028 (USD MILLION)
TABLE 106 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 107 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 108 VIETNAM SECONDARY HYPEROXALURIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 109 REST OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET, BY TYPE, 2019-2028 (USD MILLION)
図表一覧
LIST OF FIGURES
FIGURE 1 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SEGMENTATION
FIGURE 12 LOW DIETARY AWARENESS IN UPPER SOCIO-ECONOMIC SOCIETY IS EXPECTED TO DRIVE THE ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET IN 2021 & 2028
FIGURE 14 REGULATORY FRAMEWORK FOR PROBIOTICS
FIGURE 15 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET
FIGURE 16 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020
FIGURE 17 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, 2020
FIGURE 21 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUGS CLASS, 2020-2028 (USD MILLION)
FIGURE 22 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 23 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 24 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020
FIGURE 25 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 26 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, CAGR (2021-2028)
FIGURE 27 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 28 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020
FIGURE 29 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 30 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 31 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 33 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 34 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 35 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: SNAPSHOT (2020)
FIGURE 37 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2020)
FIGURE 38 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 39 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 40 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: BY TYPE (2021-2028)
FIGURE 41 ASIA-PACIFIC SECONDARY HYPEROXALURIA DRUG MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
